Becton, Dickinson and Company (NYSE:BDX) Releases FY 2025 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 14.300-14.600 for the period, compared to the consensus EPS estimate of 14.350. The company issued revenue guidance of $21.7 billion-$21.9 billion, compared to the consensus revenue estimate of $21.9 billion.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded up $1.09 during midday trading on Friday, reaching $228.30. The stock had a trading volume of 1,343,209 shares, compared to its average volume of 2,164,556. The stock has a market cap of $66.21 billion, a P/E ratio of 38.45, a P/E/G ratio of 1.80 and a beta of 0.40. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The firm has a fifty day simple moving average of $231.90 and a two-hundred day simple moving average of $234.05. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. On average, equities analysts expect that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.82%. Becton, Dickinson and Company’s payout ratio is 70.03%.

Becton, Dickinson and Company declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on BDX shares. Piper Sandler upped their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $283.00.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $221.01, for a total value of $990,787.83. Following the transaction, the executive vice president now owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. This trade represents a 15.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David Shan sold 500 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the sale, the executive vice president now directly owns 5,741 shares in the company, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.